Our Pricing

Complete Mounjaro to Wegovy Dose Conversion & UK Pricing

Published on: June 03, 2026

Understanding mounjaro to wegovy conversion uk protocols is essential for patients considering a switch between these two leading weight loss medications. While both are injectable GLP-1 receptor agonists licensed by the MHRA, they work through different mechanisms and require careful dose equivalency assessment by a UK prescriber. At Cured Pharmacy, our clinical team provides personalised switching guidance with transparent pricing from £135.00 for Wegovy and from £135.00 for Mounjaro.

Understanding Mounjaro to Wegovy Conversion UK Protocols

Switching from Mounjaro (tirzepatide) to Wegovy (semaglutide) requires clinical consideration because these medications act through different receptor pathways. Mounjaro is a dual GIP/GLP-1 receptor agonist, whilst Wegovy targets only the GLP-1 receptor [1]. This fundamental difference means there is no direct milligram-to-milligram dose equivalency between the two treatments.

UK prescribers typically assess your current Mounjaro dose, treatment duration, weight loss progress, and tolerance profile before determining an appropriate Wegovy starting dose. Most patients transitioning from Mounjaro restart Wegovy at the standard 0.25mg weekly dose and follow the manufacturer's escalation schedule, rather than jumping directly to a higher maintenance dose [2]. This approach minimises gastrointestinal side effects and allows your body to adjust to the new medication mechanism.

Clinical evidence suggests that patients established on higher Mounjaro doses (10mg or 15mg weekly) may experience continued weight loss on Wegovy's maximum 2.4mg dose, though the magnitude of effect may differ. The STEP 1 trial demonstrated an average 14.9% body weight reduction with semaglutide 2.4mg over 68 weeks, whilst SURPASS-1 showed tirzepatide 15mg produced 21% average reduction over 40 weeks [1][3]. Your UK prescriber will monitor your response during the transition period and adjust accordingly.

Mounjaro Wegovy Dose Equivalent: Clinical Comparison

Establishing a mounjaro wegovy dose equivalent is not straightforward due to their differing mechanisms of action. Tirzepatide's dual receptor activity produces greater weight loss outcomes in clinical trials compared to semaglutide, meaning a lower Mounjaro dose may produce similar effects to a higher Wegovy dose [1]. However, individual patient response varies significantly, making personalised assessment essential.

Clinical studies provide some guidance on comparative efficacy. Research comparing tirzepatide 10mg weekly to semaglutide 2.4mg weekly showed tirzepatide produced approximately 5-7% greater total body weight reduction over similar timeframes [4]. This suggests patients on Mounjaro 10mg transitioning to Wegovy's maximum 2.4mg dose should expect continued weight loss, though potentially at a reduced rate compared to their Mounjaro trajectory.

For patients on Mounjaro maintenance doses of 5mg, 10mg, or 15mg weekly, UK prescribers typically recommend transitioning to Wegovy using the standard dose escalation schedule starting at 0.25mg. This cautious approach, endorsed by clinical guidelines, allows proper tolerance assessment and reduces the risk of significant gastrointestinal adverse events during the medication switch [2].

Practical Dose Transition Guidelines

When switching from mounjaro to wegovy uk protocols, timing matters. Most UK prescribers recommend administering your first Wegovy dose one week after your last Mounjaro injection, maintaining the weekly injection schedule without overlap. This prevents excessive GLP-1 receptor stimulation whilst avoiding gaps in treatment that might trigger increased appetite or blood sugar fluctuations. Your prescriber may adjust this timing based on your individual tolerance and any side effects experienced on Mounjaro.

Switching From Mounjaro to Wegovy UK: Cost Considerations

Cost is a primary factor driving many UK patients to consider switching from mounjaro to wegovy uk options. At Cured Pharmacy, Wegovy starts from £124.99 compared to Mounjaro from £124.99 representing significant monthly savings for patients paying privately. Over a 12-month treatment course, this price difference can amount to substantial savings whilst maintaining effective weight management support.

Beyond the medication cost itself, UK patients should consider the complete treatment investment including ongoing prescriber reviews, potential dose adjustments, and monitoring requirements. Both medications require regular clinical follow-up to assess efficacy, tolerance, and appropriateness for continued use. At Cured Pharmacy, all prescription treatments include free online consultations with UK-registered prescribers, ensuring you receive comprehensive clinical support regardless of which medication you choose.

Some patients find that despite the higher cost, Mounjaro's dual-action mechanism produces superior weight loss outcomes that justify the additional expense. Others achieve their weight management goals effectively on Wegovy at the lower price point. Your UK prescriber will help you weigh these clinical and financial considerations to determine the most appropriate treatment for your individual circumstances and budget.

Long-Term Treatment Planning

Weight loss medications work best as part of a comprehensive lifestyle programme including dietary modifications and increased physical activity. Whether you continue with Mounjaro or switch to Wegovy, sustainable results require ongoing commitment to behaviour change. UK clinical guidelines recommend regular review appointments every 3-6 months to assess treatment effectiveness, with discontinuation considered if you haven't achieved at least 5% body weight reduction after 6 months at the maximum tolerated dose [5].

Tirzepatide to Semaglutide Conversion: What to Expect

Understanding the tirzepatide to semaglutide conversion process helps set realistic expectations during your medication transition. Most patients experience a continuation of weight loss when switching from Mounjaro to Wegovy, though the rate of loss may change. Clinical data suggests semaglutide produces steady, sustained weight reduction averaging 1-2% body weight per month during the dose escalation phase [3].

Common experiences during the conversion period include temporary changes in appetite regulation, as your body adjusts to the single-pathway GLP-1 mechanism after dual GIP/GLP-1 stimulation. Some patients report increased hunger during the first 2-4 weeks on lower Wegovy doses compared to their previous Mounjaro maintenance dose. This typically normalises as you progress through the Wegovy dose escalation schedule towards the 2.4mg maintenance dose.

Gastrointestinal side effects represent the most frequently reported concern during medication switches. Nausea, altered bowel habits, and reduced appetite affect approximately 40-50% of patients starting semaglutide, though these effects are generally mild to moderate and diminish over time [2][3]. Starting Wegovy at the lowest 0.25mg dose and following the gradual escalation protocol significantly reduces the severity and duration of these side effects compared to starting at higher doses.

Mounjaro vs Wegovy Dosing Chart: Clinical Escalation Schedules

Both Mounjaro and Wegovy follow structured dose escalation schedules designed to optimise efficacy whilst minimising side effects. Mounjaro starts at 2.5mg weekly for four weeks, then increases to 5mg, with further escalations to 7.5mg, 10mg, 12.5mg, and a maximum of 15mg weekly based on individual response and tolerance [1]. Each dose increase occurs at minimum four-week intervals, allowing your body to adapt to the medication's effects.

Wegovy's escalation schedule begins at 0.25mg weekly for four weeks, progressing to 0.5mg, 1mg, 1.7mg, and finally the maintenance dose of 2.4mg weekly. This more gradual initial escalation (0.25mg vs 2.5mg starting doses) reflects semaglutide's potent GLP-1 receptor activity and helps reduce the incidence of gastrointestinal adverse events [2]. The entire escalation to maximum dose takes approximately 16-20 weeks for both medications.

UK prescribers may adjust these standard schedules based on your individual tolerance. If you experience significant side effects at any dose level, your prescriber might recommend staying at your current dose for an additional four weeks before attempting the next increase, or selecting a lower maintenance dose that balances efficacy with tolerability. Clinical trials show that even submaximal doses of both medications produce clinically meaningful weight loss in most patients [1][3].

Monitoring During Dose Transitions

Regular monitoring during your mounjaro to wegovy conversion uk journey ensures optimal outcomes and early identification of any concerns. Your UK prescriber will typically schedule follow-up consultations at 4-week intervals during the Wegovy escalation phase, assessing weight loss progress, side effect profile, and treatment adherence. Blood pressure, heart rate, and in some cases blood glucose monitoring may be recommended, particularly for patients with pre-existing cardiovascular or metabolic conditions.

Wegovy After Mounjaro UK: Patient Outcomes and Expectations

Real-world evidence from UK patients using wegovy after mounjaro uk transitions shows varied but generally positive outcomes. Many patients report continued weight loss or successful weight maintenance on Wegovy following their Mounjaro course, particularly when combined with sustained lifestyle modifications. The key to success lies in maintaining realistic expectations and understanding that weight loss trajectories differ between the two medications.

Clinical data indicates that patients who achieved significant weight loss on Mounjaro (15% or more total body weight reduction) typically maintain most of this loss when transitioning to Wegovy, with some experiencing additional modest reductions. Those switching primarily for cost reasons rather than clinical necessity generally report satisfaction with Wegovy's efficacy, particularly once reaching the 2.4mg maintenance dose [3][4].

Long-term treatment adherence remains the strongest predictor of sustained weight management success regardless of which medication you use. UK guidelines emphasise that both Mounjaro and Wegovy work most effectively as part of a comprehensive weight management programme including dietary counselling, increased physical activity, and behavioural support. At Cured Pharmacy, our UK clinical team provides ongoing guidance to support your long-term success, whether you continue with Mounjaro or switch to Wegovy based on your individual needs and circumstances.

Scientific References

1. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. NICE Technology Appraisal Guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or switching between weight loss treatments. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment, lifestyle modifications, and metabolic response.